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Inhibited, trapped or adducted: the optimal
selective synthetic lethal mix for BRCAness
BRCA1 and BRCA2 proteins have important roles in DNA repli-
cation fork stabilisation and a specialised form of DNA repair
termed homologous recombination (HR) [1]. They are compo-
nents of the Fanconi anaemia protein network [2, 3]. A hallmark
of deficiency in this network is sensitivity to DNA crosslinks
induced by platinum agents and mitomycin C [4, 5]. Historically
platinum chemotherapy has only shown modest activity in
advanced breast cancer excepting those with chemotherapy naı¨ve
disease [6, 7] but recent uncontrolled studies have suggested sig-
nificant activity for single agent platinum agents in BRCA1 and
BRCA2 germline mutation carriers [8]. The TNT phase III trial
has recently reported positive interaction between the presence of
germline mutation but not epigenetic change in these genes and
specific treatment effect; with a doubling of response to carbopla-
tin but no effect of mutation on standard of care taxane response
in advanced breast cancer [9].
The re-positioning of poly(ADP-ribose) polymerase (PARP)
inhibitors, originally developed to enhance the therapeutic effects
of DNA damage inducing cancer therapy, as a single agent ther-
apy for BRCA1 or BRCA2 deficient cancers has become a poster
child for the therapeutic exploitation of the concept of synthetic
lethality [9].
PARPs are a family of enzymes the members of which induce
the NADþ-dependent polymerisation of poly(ADP-ribose)
(PAR). PARP1 is thought to be the most relevant family member
for therapeutic targeting although current PARP inhibitors target
both PARP1 and PARP2.
PARP1 function is required during the repair of lesions in one
strand of the DNA template that generate single-strand breaks
(SSBs). Upon the generation of an SSB, PARP1 binds to the break
and uses NADþ to generate PAR polymers upon itself (auto-
PARylation) and on chromatin-associated proteins relaxing
chromatin and recruiting DNA damage response (DDR) proteins
and repair effectors [10–14]. Cumulative auto-PARylation causes
the dissociation of PARP1 from DNA. PARP inhibitors block
NADþ binding and PARylation for the duration of the inhibi-
tor’s engagement of the NADþ site. Prolonged occupancy can
prevent PARP dissociation from the SSB [15]. This results in
both accumulation of unrepaired SSBs and the trapping of
PARP1 protein on the chromatin [16]. Repairing the double-
strand break that follows arrival at the scene of DNA replication
fork, and trapped PARP requires cells to have DDR sensing and
signalling proteins, BRCA1 and BRCA2 associated HR repair and
DNA replication bypass pathways active for cell survival. PARP1
itself is also directly involved in the repair of ‘collapsed forks’ and
in mechanisms of restart of stalled forks.
Current PARP-targeting agents act both as inhibitors of the
catalytic activity of PARP1, effecting the formation of PAR at sites
of DNA damage, but can also trap PARP1 onto DNA at sites of
the PARP1 DNA interaction. While all PARP inhibitors currently
in clinical development significantly inhibit catalytic activity,
there is considerable variability between compounds in their
PARP trapping effects given equimolar drug exposure [17]. This
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is likely explained by variable physico-chemical properties and
effects on target binding dynamics [18]. Talazoparib is the most
potent of the class at trapping PARP1 with niriparib, olaparib
and rucaparib having significant effect but veliparib very little
trapping despite catalytic inhibition. It was originally thought
that loss of PARP1 and its catalytic function was the main driver
of synthetic lethal effect with BRCA1 and BRCA2 mutation.
However, preclinical data indicating the need for the presence of
PARP1 protein suggest that it is the trapping of PARP as well as
its catalytic inhibition that drives therapeutic effect [16]. A num-
ber of trials have now reported the maximum tolerated doses and
levels of activity of single agent PARP inhibitors with variable
trapping effects [15]. Although cross study comparisons must be
made with caution, as patient characteristics are variable, two rel-
evant observations emerge: there appears to be a relationship
between maximum tolerated dose and trapping potency, and it
would seem that single agent response to potent trapping com-
pounds in BRCA1 and BRCA2 mutation carriers has been higher
[19, 20] than for the less potent trapping agent veliparib [18, 21].
In this issue, Han and colleagues report the BROCADE rando-
mised phase II trial that examines the efficacy of veliparib in com-
bination with temozolomide- or platinum-based chemotherapy
in BRCA1 or BRCA2 germline mutation associated advanced
breast cancer [22]. As well as PARP1’s role in the repair of endog-
enous DNA damage, its activity is also required for the repair of
chemotherapy-induced DNA lesions. Synergy with PARP inhibi-
tors is most marked with topoisomerase 1 inhibitors and temozo-
lomide. While synergy with the former relies only on inhibition
of the catalytic activity of PARP1, synergy with temozolomide is
significantly dependent upon trapping of PARP at DNA SSBs.
While PARP inhibitors and platinum agents combine to increase
cellular toxicity neither PARP1 catalytic activity nor trapping
modulate, the cellular response to platinum DNA adducts and
any effects are likely to be due to the independent effects of both
agents on DNA [23].
Although a generalisation, it has been challenging to combine
PARP inhibitors with chemotherapy that causes lesions in DNA
for anything other than brief periods of concomitant exposure.
Veliparib has provided the greatest quantity of study data in this
regard perhaps reflecting a great ability to find tolerable combina-
tions with chemotherapy.
In the BROCADE, phase II study patients were treated with
veliparib for the first 7 days of the treatment cycle combined with
either paclitaxel and carboplatin on day 1 or temozolomide from
days 1 to 5. The dose of veliparib was substantially lower in the
temozolomide arm (40 mg versus 120 mg BID) reflecting the rec-
ommended phase II doses of the combinations of these agents
and the presence of mechanistic synergy between veliparib and
temozolomide described above.
The combination of paclitaxel, veliparib and carboplatin has
been tested in early sporadic breast cancer in the I-SPY 2 pro-
gramme. This regimen used a lower 50 mg BID dose of veliparib
given continuously concomitant with chemotherapy and was
found to be both tolerable and to cause high levels of pathological
complete response in comparison to paclitaxel alone in the ‘triple
negative’ breast cancer subgroup [24]. An important question
arose as to whether the increase in activity could have been
achieved by carboplatin alone or was dependent upon the addi-
tional effect of PARP inhibition by veliparib. The BrightTNess
study, recently reported at ASCO [25], attempted to address this
question using the same regimen in an early ‘triple negative’
breast cancer population analogous to I-SPY2. The BROCADE
study reported here addresses a similar question: whether veli-
parib adds to the efficacy of a carboplatin paclitaxel combination
in the context of BRCA1 or BRCA2 germline mutation associated
advanced breast cancer. The study also tests the additional
hypothesis that the mechanistically synergistic combination of
temozolomide and veliparib would show greater activity than the
combination of carboplatin DNA adducts and paclitaxel.
So, what have we learnt from BROCADE? Firstly, when we
look at the comparator arm we see confirmation of very high
activity for a carboplatin-containing regimen in a population
approximately evenly split between BRCA1 and BRCA2 mutation
carriers. This is evidenced by an objective response rate of 61%
with durable progression-free survival (PFS; median 12 months).
The TNT trial has reported an objective response rate of 68% for
single agent carboplatin in the same population in contrast to
more modest activity for the licensed dose of docetaxel [9] sug-
gesting the BROCADE response rate is not a consequence of
unusually high paclitaxel response in BRCA mutation carriers
but rather that this is an effect of DNA platinum adducts on an
HR repair deficient tumour. Secondly, veliparib has a modest but
statistically significant effect on activity increasing objective
response rates from 61% to 78% but insufficient to significantly
improve PFS over that of the carboplatin and paclitaxel regimen
alone. The authors highlight the short duration of veliparib expo-
sure in each cycle and protocol prohibition of the continuation of
single agent veliparib in the face of withdrawal of the chemother-
apy combination due to toxicity. This is not the case in the
follow-on phase III trial BROCADE3. Thirdly, this modest
increase in activity does not appear to come at the price of any
significant increase in normal tissue toxicity. Finally, we see that
the mechanistically synergistic combination of temozolomide
and veliparib has significantly less activity than paclitaxel and car-
boplatin. The latter suggesting that veliparib, despite catalytic
inhibition of repair at temozolamide-induced SSB sites sufficient
to create cytotoxicity and define a recommended maximum
phase II dose, has less selective synthetic lethal effect in BRCA1 or
BRCA2 deficient breast cancer cells than that of a carboplatin reg-
imen. This supports the notion that to exploit an HR deficiency
to maximum effect, it is the trapping of PARP at DNA breaks or
the creation of adducts on DNA caused by platinum salts that
generate the toxic lesions that are required. That said, veliparib
despite lack of synergy with platinum and use of a brief low-dose
schedule, does somewhat add to the effect of platinum while
appearing more tolerable than the combinations of potent
PARP1 trapping inhibitors with platinum reported to date [26].
We have also to infer that veliparib given intermittently, even
when enhanced by temozolomide-induced SSBs, appears to have
substantially less efficacy than single agent PARP inhibitors with
potent PARP1 trapping activity used in a similar metastatic treat-
ment contexts [27].
Although the context, design and veliparib dosing differ in the
BrightTNess TNBC neo-adjuvant trial [24], this study supports
the BROCADE result in several ways. BrightTNess, like I-SPY2
showed an increase in activity of paclitaxel chemotherapy,
assessed by the primary objective of effect on pathological com-
plete response, with the addition of veliparib and carboplatin.
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Importantly the design and result support the conclusion that
this effect was driven by carboplatin with little additional effect of
veliparib, even in the small BRCA1 and BRCA2 mutation carrier
sub-population recruited.
What can we take home from this study? BROCADE provides
further evidence, supporting the report of the TNT trial that plat-
inum containing regimens are highly active and have important
effects on survival end points in BRCA mutation carriers, in a first
or second line relapse setting. A combination of carboplatin and
paclitaxel with veliparib, an oral PARP inhibitor with PARP
binding characteristics that causes catalytic inhibitory effect but
low PARP trapping, is highly tolerable and shows a signal of addi-
tive efficacy insufficient to significantly change PFS. The authors
posit that this signal may be converted to a clinically meaningful
effect on a PFS end point through longer exposure to higher dose
single agent veliparib after cessation of chemotherapy. We must
wait for BROCADE3 (NCT02163694) to report to know if this is
indeed the case. Meanwhile the potent PARP inhibitor olaparib
has been shown to be superior as a single agent targeted therapy
compared with physicians choice of non-platinum post-taxane
standard of care chemotherapies in the phase III OlympiaD study
in the same population with marketing approval being sought in
this indication [27]. In OlympiaD objective response with a non-
chemotherapy oral regimen was similar to that shown with car-
boplatin in TNT and to three-weekly paclitaxel and carboplatin
in BROCADE. The PFS achieved using the two paclitaxel carbo-
platin-based regimens used in BROCADE compare favourably
with those in the OlympiaD study. Cross-study comparisons
should again be interpreted with caution as the OlympiaD trial
accrued a more heavily pre-treated population approximately
30% of whom had received prior platinum-based therapy.
Beyond the primary hypotheses around effect of the two mech-
anistically distinct PARP inhibitors they test, BROCADE and
OlympiaD leave a number of unanswered questions around the
use of platinums and PARP inhibitors in advanced BRCA1 and
BRCA2 mutation associated breast cancer. The TNT trial, con-
ducted in advanced TNBC or BRCA1/BRCA2 mutation associ-
ated breast cancer prospectively tested the interaction between
genetic or epigenetic BRCAness and platinum versus taxane
treatment effect in first-line therapy in TNBC. The final result has
been presented [28] and awaits publication but the abstract pre-
sentation suggests BRCA1 and BRCA2 genetic testing should be
widely adopted as a patient selection biomarker with platinum
being the standard of care chemotherapy in the setting of muta-
tion. If olaparib is approved which should we use first, a platinum
regimen or a potent PARP inhibitor capable of trapping PARP1?
What remains unknown is how the efficacy of single agent potent
trapping PARP inhibitors compares with a platinum regimen
and in which sequence they should best be used. OlympiaD indi-
cates activity in a population 30% of whom had received but not
progressed on a prior platinum regimen. The non-randomised
ABRAZO study recently reported the activity of talazoparib in
platinum pre-treated disease and a positive relationship between
time since platinum exposure and level of activity [19].
Mechanisms of resistance to PARP inhibitors are increasingly
understood and seem to only partially overlap with those of plati-
num resistance [15]. The activity of platinums after PARP inhibi-
tor failure has not been significantly studied. As yet we do not
have the answer to which agent to use in what sequence, but it
will become increasingly important to understand the distinct
and overlapping biology of PARP inhibitor and platinum resist-
ance in this population of patients we now more frequently iden-
tify in our oncology clinics.
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Novel treatment options for refractory
Germ Cell Tumours: back to the bench!
Multi-disciplinary management of germ-cell tumours (GCT) is
highly effective and associated with excellent outcomes. However,
treatment of refractory GCT remains a therapeutic challenge with
very limited treatment options [1]. In patients who are refractory
to or recur after standard dose first-line therapy and subsequent
therapies including high-dose chemotherapy, only a few systemic
treatments have demonstrated activity and the prognosis of refrac-
tory patients is extremely poor with cure rates of<5% [2]. Hence,
the exploration of novel treatment options for these patients re-
mains one of the remaining priorities in management of GCT.
Results for novel, targeted agents including vascular endothelial
growth factor-tyrosine kinase inhibitors (TKI), epidermal growth
factor receptor-TKIs, mammalian target of rapamycin (mTOR) in-
hibitors, and c-Kit inhibitors have been generally disappointing
[3, 4]. The vast majority of these studies were based on a limited pre-
clinical rationale, a limited understanding of critical molecular mech-
anisms and were not biomarker driven. Without strong underlying
rationale, it is not surprising to find that responses to targeted agents
are exceedingly rare and long-term survival virtually non-existent.
Cancer immunotherapy with checkpoint inhibitors is the new
hope in oncology and is expected to significantly improve outcomes
with promising results having been reported in a variety of tumour
types. However, despite all the euphoria about immunotherapy, only
a small number of patients benefit from immunotherapy long-term
due to significant inter-tumour immune-response heterogeneity.
In this issue of Annals of Oncology, Adra et al. [5] report the re-
sults of the first prospective phase II study of a programmed cell
death-1 receptor (PD-1) inhibitor in refractory GCT. Of note,
this study included an unselected, not biomarker selected group
of refractory patients. On archival tissue, only two patients were
found to have programmed death ligand-1 (PD-L1)-positive
tumours based on PD-L1 expression on tumour and infiltrating
immune cells. Tumour tissue for PD-L1 examination was ob-
tained from various locations and time points during treatment
of patients in this study. The study was closed after the first stage
of 12 accrued non-seminoma patients due to the lack of objective
responses. Two patients were deemed to have short lived disease
stabilisation although AFP continued to increase in both patients
during the interval of radiological stability.
So, why have targeted agents and immunotherapy failed in re-
fractory GCT to date? Are targeted agents and immunotherapy
ineffective in these patients? Or are we just not selecting the ap-
propriate patients based on a sound and firm rationale?
The very vast majority of the studies on targeted therapies in
GCT as well as the current study testing PD-1 inhibition were
based on little preclinical and molecular data. The rationale for the
current study was derived from some smaller studies describing
various degrees of PD-L1 expression in GCT as well as some case
series reporting a few short-lived responses [6, 7]. Similar to other
tumour types, the predictive role of PD-L1 expression, by either
tumour cells or immune cells in the microenvironment, on check-
point inhibitor treatment outcomes in patients with GCT is en-
tirely unclear. In addition, it has been shown that PD-L1
expression can be transient, may change over time and under the
pressure of various treatments, and intra-patient and even intra-
tumour heterogeneity in PD-L1 tumour expression can exist [8].
Therefore, tumour sampling at one time point or at only one tu-
mour site or a portion of one tumour might not accurately reflect
the state of the PD-L1 expression in a patient. All studies examin-
ing PD-L1 expression in GCT as well as the current study used
archival tissue rather than fresh tumour biopsies begging the ques-
tion whether these results truly reflect the PD-L1 status of refrac-
tory patients. Moreover, PD-L1 is constitutively expressed in
spermatocytes and spermatids in seminiferous tubules of the testis
making the assessment of PD-L1 expression in orchiectomy speci-
mens even more complicated [9].
In addition, tumours constitute a dynamic milieu and inte-
grate numerous reinforcing and antagonistic signals from both
local and systemic conditions. Tumour immune response ap-
pears to be mediated by a complex combination of factors includ-
ing not only PD-1/PD-L1 expression but also the mutational
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